Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox.
Hello, everyone. Damian here with a close read of the latest blockbuster deal, a look at Novartis’ multibillion-dollar gamble, and a reminder of what Vertex Pharmaceuticals does well.
The need-to-know this morning
- Eli Lilly reported fourth-quarter earnings and revenue that topped Street consensus. Sales of Mounjaro, Lilly’s GLP-1 medicine for diabetes, totaled $2.2 billion versus $1.7 billion consensus. The same drug, recently approved as Zepbound for obesity, had sales of $176 million. For 2024, Lilly is forecasting revenue in the range of $40.4-41.6 billion, higher than current Street consensus.
- Lilly also reported results from a Phase 2 study of tirzepatide (Mounjaro/Zepbound) in the fatty liver disease known as MASH, showing 74% MASH reversal without worsening of fibrosis compared to 13% for placebo — statistically significant for the study’s primary goal. Lilly said tirzepatide also showed a “clinically meaningful” reduction in liver fibrosis, a key secondary endpoint, but missed statistical significance.
Is selling stuff to biotech a good business?
Consider yesterday’s big deal, in which Novo Holdings paid about $17 billion for the pharma contractor Catalent and then flipped three of the company’s plants to Novo Nordisk, in which it owns a controlling stake.
This article is exclusive to STAT+ subscribers
Unlock this article — plus in-depth analysis, newsletters, premium events, and networking platform access.
Already have an account? Log in
Already have an account? Log in
About the Author Reprints
To submit a correction request, please visit our Contact Us page.
STAT encourages you to share your voice. We welcome your commentary, criticism, and expertise on our subscriber-only platform, STAT+ Connect